Market Overview

Celldex Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Added Shares

Share:
Related CLDX
US Stock Futures Signal Higher Start On Wall Street
Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies
Next Week In Biotech: Salix/Valeant PDUFA, ASCO, Brain Tumor Summit (Seeking Alpha)

Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,800,000 shares of common stock at the public offering price of $7.50 per share, less underwriting discounts and commissions. Proceeds from the exercise of the option will be approximately $12.7 million, after deducting underwriting discounts and commissions. The closing of the option exercise is expected to occur on February 11, 2013, subject to customary closing conditions.

Posted-In: News Offerings

 

Related Articles (CLDX)

Around the Web, We're Loving...